Maxim Group Reiterates Buy on Pluristem Therapeutics (PSTI) Following Announced Contract with Global CRO
Tweet Send to a Friend
Maxim Group reiterated a Buy rating and $3.00 price target on Pluristem Therapeutics (NASDAQ: PSTI) following the company's announcement that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
